You are here

Daclatasvir/Asunaprevir Combo Receives ‘Breakthrough Therapy’ Designation for Hepatitis C

Treatment targets genotype 1b HCV (February 24)

The FDA has granted the dual regimen of daclatasvir and asunaprevir (Bristol-Myers Squibb) a “breakthrough therapy” designation for use in the treatment of genotype 1b chronic hepatitis C virus (HCV) infection.

The designation was based on data from an ongoing phase III clinical trial program evaluating the all-oral combination regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, without ribavirin.

According to the FDA, a breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.

An estimated 2.7 to 3.9 million people are chronically infected with HCV in the U.S.

Source: Bristol-Myers Squibb; February 24, 2014.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress